Tapering of SSRI treatment to mitigate withdrawal symptoms
Open accessThe DOI matches its Crossref record; 76 of the 81 references it cites were found in a registry or an index; 27 of the 104 sources its claims cite were checked for support.
Abstract
All classes of drug that are prescribed to treat depression are associated with withdrawal syndromes. SSRI withdrawal syndrome occurs often and can be severe, and might compel patients to recommence their medication. Although the withdrawal syndrome can be differentiated from recurrence of the underlying disorder, it might also be mistaken for recurrence, leading to long-term unnecessary medication. Guidelines recommend short tapers, of between 2 weeks and 4 weeks, down to therapeutic minimum doses, or half-minimum doses, before complete cessation. Studies have shown that these tapers show minimal benefits over abrupt discontinuation, and are often not tolerated by patients. Tapers over a period of months and down to doses much lower than minimum therapeutic doses have shown greater success in reducing withdrawal symptoms. Other types of medication associated with withdrawal, such as benzodiazepenes, are tapered to reduce their biological effect at receptors by fixed amounts to minimise withdrawal symptoms. These dose reductions are done with exponential tapering programmes that reach very small doses. This method could have relevance for tapering of SSRIs. We examined the PET imaging data of serotonin transporter occupancy by SSRIs and found that hyperbolically reducing doses of SSRIs reduces their effect on serotonin transporter inhibition in a linear manner. We therefore suggest that SSRIs should be tapered hyperbolically and slowly to doses much lower than those of therapeutic minimums, in line with tapering regimens for other medications associated with withdrawal symptoms. Withdrawal symptoms will then be minimised.
Overview
CoChat Summary
TL;DR
This review argues that SSRI withdrawal is common and that current 2–4 week linear tapers are often ineffective, and it proposes hyperbolic tapering based on PET-derived serotonin transporter (SERT) occupancy. By reducing dose in fixed steps of biological effect—e.g., approximately 10% SERT occupancy—withdrawal symptoms should be minimized.
Key findings
- SSRI withdrawal incidence varies widely: paroxetine 42–100%, fluoxetine 9–77%, and a median of 53.6% across 14 studies; the 14-day discontinuation period was associated with a 60% increase in suicide attempts compared with previous antidepressant users.
- Short tapers of 2–4 weeks show no or minimal benefit over abrupt discontinuation, whereas longer tapers perform better: paroxetine reduced by 10 mg every 2 weeks lowered withdrawal incidence from 34% to 4.6%; tapering up to 4 months produced 5.1 vs 11.7 DESS events; an average 38.6-week paroxetine taper had 6% vs 78% withdrawal with abrupt discontinuation; tapering strips allowed 71% of 1194 patients to discontinue over a median of 2 months.
- PET SERT occupancy data show a hyperbolic dose-response, so linear dose reductions cause increasingly large drops in SERT inhibition. For citalopram, 5 mg decrements from 20 mg produce SERT inhibition decreases of 3% (20→15 mg), 6% (15→10 mg), 13% (10→5 mg), and 58% (5→0 mg); even 2.5 mg→0 mg produces a 42.9% reduction and 1.25 mg→0 mg a 28% reduction, larger than 40 mg→5 mg (27.3%).
- The proposed hyperbolic regimen reduces dose by fixed intervals of biological effect, such as 10% SERT occupancy steps; for citalopram this gives 20, 9.1, 5.4, 3.4, 2.3, 1.5, 0.8, 0.37, 0 mg, with a final dose near 10% SERT occupancy. Fluoxetine may allow approximately 30% SERT occupancy steps and a three-month observation period because of its long half-life.
Methods
- Narrative review/hypothesis paper; no new primary clinical trial or patient sample is reported.
- It synthesizes existing literature on SSRI withdrawal and tapering and uses PET imaging data of SERT occupancy by SSRIs, applying law-of-mass-action/Michaelis-Menten modeling to the dose-response relationship.
- Main analysis derives hyperbolic tapering schedules and practical recommendations, including an initial test reduction, DESS monitoring, and individualization of taper rate.
Limitations
- Stated: the PET study had relatively few participants, limiting capture of individual variation; other SSRI targets beyond SERT exist though are thought downstream; it is difficult to determine whether SERT inhibition linearly corresponds to withdrawal effects, and a threshold effect is theoretically possible; striatal SERT occupancy may not directly reflect antidepressant action.
- Stated: the optimal interval between dose reductions and the timing of neuroadaptation are not established; recommendations are based on clinical experience/consensus and require randomized controlled trial confirmation.
- Evident: the proposed hyperbolic taper is not prospectively tested in this paper, and no direct clinical outcome data are presented for the specific regimen; the argument relies on secondary data and pharmacological modeling.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 12 Not valid · 33 Not checked · 24 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, a hyperbolic relationship exists between dose of SSRI and reduction of depressed mood, as demonstrated in a mega-analysis 67 ; a hyperbolic relationship has also been demonstrated between dose of SSRI and risk of withdrawal symptoms 55 .”
§ A method of tapering SSRI treatment to mitigate withdrawal symptoms > Limitations
What the sources say
- Disputedcites [55] Michelson, 2000, Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial, Br J Psychiatry sourceExperimental — accuracy not yet measured
The Symptom measures section reports no significant relationship between SSRI dose and new symptoms after treatment interruption. The Relationships to plasma drug concentrations section likewise says doses did not correlate with interruption symptoms in any drug group. It reports an association with the percentage reduction in plasma concentration across drug groups, not a hyperbolic dose–risk relationship. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, a hyperbolic relationship exists between dose of SSRI and reduction of depressed mood, as demonstrated in a mega-analysis 67 ; a hyperbolic relationship has also been demonstrated between dose of SSRI and risk of withdrawal symptoms 55 .”
§ A method of tapering SSRI treatment to mitigate withdrawal symptoms > Limitations
What the sources say
- Could not verifycites [67] Mawe, 2013, Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets, Nat Rev Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The Functional GI disorders section discusses SSRIs' effects on intestinal transit and mentions depressive symptoms in relation to SERT genotype, but it does not address how SSRI dose relates to improvement in depressed mood. Searches for a hyperbolic relationship, dose response, and a mega-analysis found no supporting passage in our copy. (LLM, conf=0.76)
- Disputedcites [55] Michelson, 2000, Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial, Br J Psychiatry sourceExperimental — accuracy not yet measured
This paper is cited for the second clause of the sentence, concerning SSRI dose and withdrawal symptoms, not the depressed-mood claim attributed to citation 67. In 'Symptom measures' (page unavailable), it reports no significant relationship between dose and new symptoms after treatment interruption; 'Relationships to plasma drug concentrations' likewise reports no dose–symptom correlation. It does not demonstrate the claimed hyperbolic relationship. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the details remain to be elucidated, SSRI withdrawal has been attributed to a relative deficiency of serotonin in the context of widespread adaptation of serotonergic receptors 9,49,64 .”
§ A method of tapering SSRI treatment to mitigate withdrawal symptoms > Neurobiology of SSRI withdrawal
What the sources say
- Partly supportedcites [9] Fava, 2015, Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review, Psychother Psychosom sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) lists decreased serotonin availability after treatment ends as a suggested mechanism of withdrawal, while emphasizing that the mechanisms remain hypothetical. It does not describe widespread adaptation of serotonergic receptors or link such adaptation to the proposed serotonin decrease. (LLM, conf=0.86)
- Could not verifycites [49] Brett, 2015, Management of benzodiazepine misuse and dependence, Aust Prescr sourceExperimental — accuracy not yet measured
The Prevention and Discontinuation sections discuss benzodiazepine withdrawal, not SSRI withdrawal. Searches for serotonin deficiency and serotonergic receptor adaptation found no passage addressing the proposed SSRI-withdrawal mechanism. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [64] Wamsley, 1987, Receptor alterations associated with serotonergic agents: an autoradiographic analysis, J Clin Psychiatry
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Paroxetine may produce a more severe withdrawal syndrome than other SSRIs because it has pronounced muscarinic antagonist effects and moderate norepinephrine transporter inhibiting effects 49,64 .”
§ A method of tapering SSRI treatment to mitigate withdrawal symptoms > Other determinants of withdrawal symptoms from SSRIs
What the sources say
- Could not verifycites [49] Brett, 2015, Management of benzodiazepine misuse and dependence, Aust Prescr sourceExperimental — accuracy not yet measured
The Prevention and Pharmacotherapy sections discuss benzodiazepine withdrawal, not paroxetine withdrawal. Searches for paroxetine, muscarinic antagonism, and norepinephrine transporter inhibition found no passage addressing the claimed comparison with other SSRIs (page numbers unavailable). (LLM, conf=0.77)
- Not checked — no full text of the sourcecites [64] Wamsley, 1987, Receptor alterations associated with serotonergic agents: an autoradiographic analysis, J Clin Psychiatry
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“All major classes of antidepressants -MAOIs, TCAs, SSRIs, and SNRIs -are associated with withdrawal symptoms 2,3 .”
§ A method of tapering SSRI treatment to mitigate withdrawal symptoms > Abstract
What the sources say
- Not checked — no full text of the sourcecites [2] Howland, 2010, Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs, J Psychosoc Nurs Ment Health Serv source
- Supportedcites [3] Haddad, 2007, Recognising and managing antidepressant discontinuation symptoms, Adv Psychiatr Treat source
The opening passage (p. 447) explicitly says discontinuation (withdrawal) symptoms occur with all antidepressant classes and names TCAs, MAOIs, SSRIs, and SNRIs. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims · 9 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence is lacking regarding strategies for discontinuation of antidepressants, and the optimal method of stopping antidepressants is currently unknown; however slow enough tapering can make withdrawal symptoms tolerable (Horowitz 2019).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Horowitz 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Review authors found four studies -Groot 2013;Himei 2006;Murata 2010;van Geffen 2005 -showing that tapering over several months results in fewer withdrawal symptoms (Horowitz 2019).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Horowitz 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Horowitz-Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,9,15”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence is emerging, however, that suggests that antidepressants, like benzodiazepines, should usually be tapered very slowly, often over several months or longer (but tailored to the individual) not 2–4 weeks as suggested by many guidelines.35,36”
From A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report (2020) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The symptoms are often far in excess, in terms of both quantity and intensity, of the problems for which the drugs were initially prescribed.10,20”
From The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services? (2021) · cites this paper as [20]
Experimental — accuracy not yet measured
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets
Mawe, G. M., & Hoffman, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.105 · Cited by 1,165
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationSSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Cited by
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“It has recently been suggested that antidepressants should be tapered down hyperbolically (by lowering the dose by smaller amounts over time) in the same manner as benzodiazepines (Horowitz and Taylor, 2019), which is further supported by a Dutch taskforce (Ruhe et al.”
BackgroundFurukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Self-citationMarsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30331-1 · Cited by 106
Metadata
- Authors
- Horowitz, M. A., & Taylor, D.
- Affiliations
- Prince of Wales Hospital (AU)
- King's College London (GB)
- Corresponding author
- Horowitz, Mark Abie
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 6
- Issue
- 6
- Pages
- 538-546
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2919124707
- Semantic Scholar
- 66ca9b8b04113e1e45135818ced27b2c0ca049c0
- Cited by
- 280
- References
- 81
- Citations by year
- 2026: 45 · 2025: 37 · 2024: 44 · 2023: 40 · 2022: 35 · 2021: 32 · 2020: 32 · 2019: 15
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (acceptedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- selective serotonin reuptake inhibitors, medication tapering, positron emission tomography, depression, benzodiazepine withdrawal, dose reduction, antidepressant discontinuation
- MeSH terms
- Dose-Response Relationship, Drug, Humans, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic, Positron-Emission Tomography, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tapering of SSRI treatment to mitigate withdrawal symptoms. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30032-x
- The paper
- Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30032-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.